Key facts: CMPS Phase III ~4‑pt MADRS gain; dosing, SPRAVATO sites

Key facts: CMPS Phase III ~4‑pt MADRS gain; dosing, SPRAVATO sites

Less than 1 min read

- COMPASS Pathways (CMPS) Phase III COMP360 showed ~4‑point MADRS improvement vs placebo; ~25% responded after one dose, ~40% after two doses three weeks apart; effects durable to 26–52 weeks.

MarketBeat - CMPS plans two initial COMPASS doses ≥3 weeks apart; physicians decide extra dosing. Company expects 2–4 annual doses per patient, will use ~8,500 SPRAVATO sites and pursue reimbursement support.

MarketBeat

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.